Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-01-26 4:15 pm Purchase | 2026-01-16 | 13G | Capricor Therapeutics, Inc. CAPR | TANG CAPITAL MANAGEMENT, LLC | 3,399,900 6.600% | 3,399,900 (New Position) | Filing History |
| 2025-11-14 4:17 pm Unchanged | 2025-09-30 | 13G | ALX Oncology Holdings Inc. ALXO | TANG CAPITAL MANAGEMENT, LLC | 0 0.000% | 0 (Unchanged) | Filing History |
| 2025-11-14 4:17 pm Unchanged | 2025-09-30 | 13G | Bolt Biotherapeutics, Inc. BOLT | TANG CAPITAL MANAGEMENT, LLC | 66,879 3.500% | 0 (Unchanged) | Filing History |
| 2025-11-14 4:17 pm Unchanged | 2025-09-30 | 13G | Compass Therapeutics, Inc. CMPX | TANG CAPITAL MANAGEMENT, LLC | 17,176,510 9.990% | 0 (Unchanged) | Filing History |
| 2025-11-14 4:17 pm Unchanged | 2025-09-30 | 13G | ESSA Pharma Inc. EPIX | TANG CAPITAL MANAGEMENT, LLC | 0 0.000% | 0 (Unchanged) | Filing History |
| 2025-11-14 4:15 pm Sale | 2025-09-30 | 13G | ALX Oncology Holdings Inc. ALXO | TANG CAPITAL MANAGEMENT, LLC | 0 0.000% | -3,158,265 (Position Closed) | Filing History |
| 2025-11-14 4:15 pm Sale | 2025-09-30 | 13G | Bolt Biotherapeutics, Inc. BOLT | TANG CAPITAL MANAGEMENT, LLC | 66,879 3.500% | -100,000 (-59.92%) | Filing History |
| 2025-11-14 4:15 pm Purchase | 2025-09-30 | 13G | Compass Therapeutics, Inc. CMPX | TANG CAPITAL MANAGEMENT, LLC | 17,176,510 9.990% | 3,680,302 (+27.27%) | Filing History |
| 2025-11-14 4:15 pm Sale | 2025-09-30 | 13G | ESSA Pharma Inc. EPIX | TANG CAPITAL MANAGEMENT, LLC | 0 0.000% | -4,300,000 (Position Closed) | Filing History |
| 2025-10-29 6:30 pm Purchase | 2025-10-27 | 13G | Galapagos N.V. GLPG | TANG CAPITAL MANAGEMENT, LLC | 5,559,674 8.400% | 649,149 (+13.22%) | Filing History |
| 2025-10-24 4:16 pm Purchase | 2025-10-17 | 13G | Immunocore Holdings plc IMCR | TANG CAPITAL MANAGEMENT, LLC | 2,605,608 5.200% | 2,605,608 (New Position) | Filing History |
| 2025-10-22 9:26 pm Purchase | 2025-10-15 | 13G | Keros Therapeutics, Inc. KROS | TANG CAPITAL MANAGEMENT, LLC | 2,418,984 7.900% | 2,418,984 (New Position) | Filing History |
| 2025-10-09 4:15 pm Purchase | 2025-10-02 | 13G | Crescent Biopharma, Inc. CBIO | TANG CAPITAL MANAGEMENT, LLC | 700,000 5.040% | 700,000 (New Position) | Filing History |
| 2025-09-23 8:34 pm Purchase | 2025-09-16 | 13G | PMV Pharmaceuticals, Inc. PMVP | TANG CAPITAL MANAGEMENT, LLC | 4,720,357 8.900% | 4,720,357 (New Position) | Filing History |
| 2025-09-19 4:15 pm Sale | 2025-09-17 | 13D | HilleVax, Inc. HLVX | TANG CAPITAL MANAGEMENT, LLC | 0 0.000% | -4,920,000 (Position Closed) | Filing History |
| 2025-09-03 4:15 pm Sale | 2025-08-29 | 13D | iTeos Therapeutics, Inc. ITOS | TANG CAPITAL MANAGEMENT, LLC | 10,000 100.000% | -3,816,692 (-99.74%) | Filing History |
| 2025-08-21 4:15 pm Sale | 2025-08-19 | 13D | CARGO Therapeutics, Inc. Common Stock CRGX | TANG CAPITAL MANAGEMENT, LLC | 10,000 100.000% | -3,049,630 (-99.67%) | Filing History |
| 2025-08-14 4:15 pm Purchase | 2025-06-30 | 13G | Bolt Biotherapeutics, Inc. BOLT | TANG CAPITAL MANAGEMENT, LLC | 166,879 8.700% | 166,879 (New Position) | Filing History |
| 2025-08-14 4:15 pm Purchase | 2025-06-30 | 13G | Compass Therapeutics, Inc. CMPX | TANG CAPITAL MANAGEMENT, LLC | 13,496,208 9.800% | 2,443,576 (+22.11%) | Filing History |
| 2025-08-14 4:15 pm Purchase | 2025-06-30 | 13G | CytomX Therapeutics, Inc. CTMX | TANG CAPITAL MANAGEMENT, LLC | 11,065,662 7.000% | 4,347,837 (+64.72%) | Filing History |